VolitionRX Limited

And welcome to VolitionRx Limited second quarter 2021 financial results and business update conference call and webcast. At this time, all participants are in listen-only mode. If anyone should require operator assistance, please press star zero on your telephone keypad. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Scott Powell, Executive Vice President, Investor Relations. Please go ahead.

Thank you and welcome everyone to today's earnings conference call for VolitionRx Limited. This call will cover Volition's financial and operating results for the second quarter of 2021, along with a discussion of our recent activities and key upcoming milestones. Following our prepared remarks, we will open the conference call to a question and answer session. Also on our call today are Mr. Cameron Reynolds, President and Chief Executive Officer, Mr. Terry Cuse, our Chief Financial Officer, and Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development, LLC. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on our beliefs as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may vary significantly based on a number of factors that may cause the actual results or events to be materially different from future results, performance, or achievements expressed or implied by these statements. We have identified various risk factors associated with our operations in our most recent annual report on Form 10-K, quarterly reports on Form 10Q and other filings with the Securities and Exchange Commission. We do not undertake an obligation to update any forward booking statements made during the course of this call. I would now like to turn the call over to our President and Chief Executive Officer, Mr. Cameron Reynolds. Cameron?

Thank you, everyone, for joining Volition's conference call today. I especially appreciate it given how busy you all are during the earnings call season. And speaking of busy, our whole team has worked very hard during the pandemic towards our goal of becoming a commercial enterprise. As you might remember from our last call, we have had quite a start to the year and made excellent progress in developing a range of products based on our proprietary UQ platform. In addition to making significant progress in negotiations over a number of potential licensing arrangements. I expect that we will have a lot of news throughout the remainder of this year on progress with our numerous commercialization efforts. I will be updating you today on our patents, publications, products, people, and most importantly, progress within our four key pillars, NewQ, NewQ Vet, NewQ Nets, and NewQ Capture. And I'm delighted that Dr. Tom Butera, Chief Executive Officer of our veterinary subsidiary, is joining us to update on the fantastic progress and upcoming plans for new QVET. To start off, however, I'll quickly hand over to Tereg for the financial report.